BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Allergy to pollen
,
Pancreas
,
Metabolism of nitric oxide
,
Doxorubicin
,
rs6983267
,
SNCA
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CI-1033
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
WIF1
GPX3
HBB
COL11A1
RBP4
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
cytosol
regulation of nitrogen compound metabolic process
organic cyclic compound binding
heterocyclic compound binding
vesicle
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Prostate cancer LNCAP cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-103…
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previous…
The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and i…
The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in hum…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy…
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small …
3T MRI CIED Post-Approval Study
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ